ArticleMolecular biology of the cell2012
Direct inhibition of myosin II effectively blocks glioma invasion in the presence of multiple motogens.
Article in Molecular biology of the cell, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 98 citations in OpenAlex.
- Septins buffer actomyosin forces to protect the nucleus from genotoxic mechanical stress.The Journal of cell biology · 2026Article
- Mechanical regulation of microenvironment remodeling in brain tumors: from mechanism to therapy.Journal of neuroinflammation · 2026Review
- Optogenetic stimulation of Lbc GEF-mediated Rho activity dynamics promotes cell invasion.Molecular biology of the cell · 2025Article
- Article
- Article
- A Benzodiazepine-Derived Molecule That Interferes with the Bio-Mechanical Properties of Glioblastoma-Astrocytoma Cells Altering Their Proliferation and Migration.International journal of molecular sciences · 2025Article
- Structure, regulation, and mechanisms of nonmuscle myosin-2.Cellular and molecular life sciences : CMLS · 2024Review
- Peritumoral Brain Zone in Astrocytoma: Morphology, Molecular Aspects, and Clinical Manifestations (Review).Sovremennye tekhnologii v meditsine · 2024Review
- Development of a Synthetic, Injectable Hydrogel to Capture Residual Glioblastoma and Glioblastoma Stem-Like Cells with CXCL12-Mediated Chemotaxis.Advanced healthcare materials · 2023Article
- Jamming Transitions in Astrocytes and Glioblastoma Are Induced by Cell Density and Tension.Cells · 2022Article
- Cancer as a biophysical disease: Targeting the mechanical-adaptability program.Biophysical journal · 2022Review
- Mechanics and functional consequences of nuclear deformations.Nature reviews. Molecular cell biology · 2022Review
- GFAP splice variants fine-tune glioma cell invasion and tumour dynamics by modulating migration persistence.Scientific reports · 2022Article
- Targeting the cytoskeleton against metastatic dissemination.Cancer metastasis reviews · 2021Review
- Estimating Glioblastoma Biophysical Growth Parameters Using Deep Learning Regression.Brainlesion : glioma, multiple sclerosis, stroke and traumatic brain injuries. BrainLes (Workshop) · 2021Article
- 4-Hydroxyacetophenone modulates the actomyosin cytoskeleton to reduce metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Integrated Biophysical Modeling and Image Analysis: Application to Neuro-Oncology.Annual review of biomedical engineering · 2020Review
- Predicting Confined 1D Cell Migration from Parameters Calibrated to a 2D Motor-Clutch Model.Biophysical journal · 2020Article
- From cells to tissue: How cell scale heterogeneity impacts glioblastoma growth and treatment response.PLoS computational biology · 2020Article
- The Expressions and Mechanisms of Sarcomeric Proteins in Cancers.Disease markers · 2020Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Anaplastic gliomas, the most common and malignant of primary brain tumors, frequently contain activating mutations and amplifications in promigratory signal transduction pathways. However, targeting these pathways with individual signal transduction inhibitors does not appreciably reduce tumor invasion, because these pathways are redundant; blockade of any one pathway can be overcome by stimulation of another. This implies that a more effective approach would be to target a component at which these pathways converge. In this study, we have investigated whether the molecular motor myosin II represents such a target by examining glioma invasion in a series of increasingly complex models that are sensitive to platelet-derived growth factor, epidermal growth factor, or both. Our results lead to two conclusions. First, malignant glioma cells are stimulated to invade brain through the activation of multiple signaling cascades not accounted for in simple in vitro assays. Second, even though there is a high degree of redundancy in promigratory signaling cascades in gliomas, blocking tumor invasion by directly targeting myosin II remains effective. Our results thus support our hypothesis that myosin II represents a point of convergence for signal transduction pathways that drive glioma invasion and that its inhibition cannot be overcome by other motility mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.